SOM 生物技术公司完成了治疗亨廷顿舞蹈症的 IIb 期研究的招募过程

于由Daniela Carvalho发布

基于独特的专有人工智能平台（SOMAIPRO®）的临床阶段药物研发公司SOM生物技术公司（SOM Biotech）欣喜地宣布，SOM3355治疗亨廷顿舞蹈症的IIb期临床研究招募工作已经完成。

在IIa期研究中，患者证实了该药物具有良好的安全性和对舞蹈动作的临床疗效，之后，SOM生物技术公司开展了一项为期12周的双盲、安慰剂对照剂量IIb期研究，评估两种剂量方案的疗效和安全性。研究结果预计将于今年年底公布。

点击此处阅读 完整新闻稿.

分类： 新闻研究
标签：

0 条评论

发表回复

头像占位符

您的电子邮箱地址不会被公开。 必填项已用*标注

相关文章

新闻

Prilenia’s Pridopidine for Huntington’s Disease Accepted for European Marketing Authorisation Review

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing Authorization Application (MAA) with the 阅读更多...

新闻

IROS, Prilenia and International Huntington’s Disease Association collaborate on first-ever Huntington’s disease (HD) trial in the MENA region

Abu Dhabi, UAE; June 19, 2024: IROS, an Abu Dhabi-based contract research organization (part of the M42 group), has partnered with Prilenia Therapeutics, a clinical-stage biotech company, and the International Huntington’s Disease Association (IHA) to 阅读更多...

新闻

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for HD

“We are very pleased with these new data demonstrating a statistically significant, dose-dependent slowing of the progression of Huntington’s disease and lowering of NfL in the CSF at 24 months,” stated Walid Abi-Saab, M.D., chief medical 阅读更多...

zh_CNChinese
en_USEnglish arArabic bg_BGBulgarian cs_CZCzech da_DKDanish nl_NLDutch etEstonian fiFinnish fr_FRFrench de_DEGerman elGreek hu_HUHungarian id_IDIndonesian it_ITItalian jaJapanese lvLatvian lt_LTLithuanian pl_PLPolish pt_PTPortuguese ro_RORomanian ru_RURussian sk_SKSlovak sl_SISlovenian es_ESSpanish sv_SESwedish tr_TRTurkish ukUkrainian zh_CNChinese
跳至内容